Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Venetoclax plus azacitidine in treatment-naïve higher-risk MDS

Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, gives an update on a Phase Ib study evaluating venetoclax plus azacitidine in treatment-naïve higher-risk myelodysplastic syndromes (MDS) (NCT02942290), including patients with TP53, ASXL1, U2AF1, and RUNX1 mutations. The primary objectives were to establish the safety profile and the recommended Phase II dose (RP2D) for this combination, and secondary objectives included overall response rate (ORR) and overall survival (OS). At this updated analysis, an ORR of 84% was observed. Meaningful clinical and molecular responses were observed across the mutational spectrum, including in patients with poor prognostic mutations in TP53, ASXL1 and RUNX1, which supports an all-comers approach. In addition, variant allele frequency (VAF) reductions below the level of detection were observed quickly and across the mutational spectrum, and patients who achieved a complete response (CR) at the time of serial sample acquisition had a more significant VAF reduction in comparison to patients who had stable disease or progressive disease. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.